Section Arrow
Quote
RGEN.NASDAQ
- Repligen Corp
Quotes are at least 15-min delayed:2025/09/17 05:54 EDT
Pre Market
Last
 120.01
+0.26 (+0.22%)
Bid
116.25
Ask
191.6
High 122.14 
Low 119.52 
Volume 288 
Regular Hours
Last
 119.75
+6.01 (+5.28%)
Day High 
120.16 
Prev. Close
113.74 
1-M High
127.48 
Volume 
1.36M 
Bid
116.25
Ask
191.6
Day Low
112.84 
Open
113.56 
1-M Low
112.71 
Market Cap 
6.40B 
Currency USD 
P/E 594.78 
%Yield -- 
10-SMA 118.84 
20-SMA 120.36 
50-SMA 120.56 
52-W High 182.52 
52-W Low 102.965 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.25/1.87
Enterprise Value
7.07B
Balance Sheet
Book Value Per Share
36.65
Cash Flow
Cash Flow Yield
0.02
Income Statement
Total Revenue
29.36M
Operating Revenue Per Share
11.91
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
BNGOBionano Genomics Inc1.78-0.99-35.74%0.02PE
Pre Market 1.79 +0.01 +0.56%
HBIOHarvard Bioscience0.4849+0.0454+10.33%-- 
Pre Market 0.463 -0.0219 -4.52%
AVTRAvantor12.71+0.32+2.58%12.27PE
Pre Market 12.71 0 0.00%
BAXBaxter International23.87+0.07+0.29%140.32PE
Pre Market 24 +0.13 +0.54%
MBOTMicrobot Medical3.34-0.08-2.34%-- 
Pre Market 3.39 +0.05 +1.50%
Quotes are at least 15-min delayed：2025/09/17 05:54 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.